Global Onychomycosis Market Size study & Forecast, by Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Other Types) by Treatment (Oral, Topical, Others) and Regional Analysis, 2022-2029

Global Onychomycosis Market Size study & Forecast, by Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Other Types) by Treatment (Oral, Topical, Others) and Regional Analysis, 2022-2029

Global Onychomycosis Market is valued at approximately USD 3.3 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 4.56% over the forecast period 2022-2029. Onychomycosis is a fungal infection of the nails, and can also be referred to as dermatophytic onychomycosis. This can be a cause of dermatophytes and nondermatophytic molds. The symptoms begin with physical alterations to the nail and surrounding skin. The nail and tissue frequently turn white or yellow, and the nails might thicken and become brittle, making them more likely to break. Physical problems in this condition might deteriorate noticeably and cause pain and inflammation if not managed. The high prevalence of Onychomycosis infections, increasing investments in the R&D of novel drugs, increasing ageing population, rising incidence of chronic diseases, and easy accessibility of antifungal drugs are the factors driving the growth of the market.

According to the National Library of Medicine, there is 10% of the Onychomycosis infected population across the globe. Trichophyton rubrum was estimated to be the main infecting organism. Nondermatophyte mould and dermatophytes are the other causes of Onychomycosis infections. T. rubrum organisms were found in 98% of the infections. Additionally, The R&D expenditure in the pharmaceutical industry amounted to 83 billion dollars in 2019. Between 2010 and 2019, the Food and Drug Administration (FDA) approved 38 new medications on average, which is 60% more than it did on an annual average over the preceding ten years. Increasing Onychomycosis infections and increasing R&D investments and development of new drugs are the major factors driving the market growth. Other important components driving market increase are the increasing ageing population, rising incidence of chronic diseases, and easy accessibility of antifungal drugs. Furthermore, rising awareness about the treatment of Onychomycosis and the growing Diabetic Population are the factors creating major market opportunities in the forecast period. However, the lack of awareness of onychomycosis infections stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Onychomycosis Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising prevalence of Onychomycosis infections, increasing healthcare expenditures, increase in the awareness of Onychomycosis drugs, and increasing government initiatives in R&D. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as high incidence of Onychomycosis infections, a growing geriatric population, increasing urbanization and focus of key players on investing in R&D.

Major market player included in this report are:
Bausch Health Companies Inc.
Gsk Plc
Abbott
Pfizer Inc.
Bayer Ag
Teva Pharmaceutical Industries, Ltd.
Cipla Inc.
Novartis Ag
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.

Recent Developments in the Market:
In March 2021, The Tianjin Institute of Pharmaceutical Research and HUYABIO International joint venture, submitted a new drug application efinaconazole, as Jublia™ for the treatment of onychomycosis.
In July 2021, Kaken Pharmaceutical (KKPCF) and Almirall S.A., a global biopharmaceutical company specializing in skin health, announced that they have signed a license and distribution agreement under which Kaken Pharmaceutical gives Almirall the exclusive right to develop and market the topical formulation of efinaconazole in Europe.
Global Onychomycosis Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Treatment, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Other Types

By Treatment:
Oral
Topical
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned
Bausch Health Companies Inc.
Gsk Plc
Abbott
Pfizer Inc.
Bayer Ag
Teva Pharmaceutical Industries, Ltd.
Cipla Inc.
Novartis Ag
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.